{"id":7002,"date":"2011-11-17T11:43:50","date_gmt":"2011-11-17T16:43:50","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=7002"},"modified":"2011-11-17T11:43:50","modified_gmt":"2011-11-17T16:43:50","slug":"diagnostics-developer-secures-100m-series-c-financing","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=7002","title":{"rendered":"Diagnostics Developer Secures $100M Series C Financing"},"content":{"rendered":"<p><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/08\/CurrencyDice_M4DGROUP_Flickr.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-full wp-image-5768\" title=\"Currency Dice\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/08\/CurrencyDice_M4DGROUP_Flickr.jpg\" alt=\"Currency dice (MD4 Group\/Flickr)\" width=\"300\" height=\"200\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/08\/CurrencyDice_M4DGROUP_Flickr.jpg 300w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/08\/CurrencyDice_M4DGROUP_Flickr-150x100.jpg 150w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a>Biocartis, a diagnostic systems company in Lausanne, Switzerland says it completed raising <a href=\"http:\/\/www.biocartis.com\/cms\/index.php?mact=News,cntnt01,detail,0&amp;cntnt01articleid=45&amp;cntnt01origid=67&amp;cntnt01detailtemplate=one_news&amp;cntnt01returnid=67\">\u20ac71 million<\/a> (US$100 million) in series C equity funds, led by the company&#8217;s senior management and\u00a0 backed by current and new investors, as well as industrial collaborators. Series C financing is the third round of equity funding after start-up.<\/p>\n<p>Biocartis develops compact <a href=\"http:\/\/www.biocartis.com\/cms\/index.php?page=molecular-diagnostics-platform\">molecular and genomic diagnostic systems<\/a>, considered key to the adoption of personalized medicine. The company expects to launch its first system &#8212; code named Apollo &#8212; in 2013, which it says has been modeled after consumer electronics designed for everyday use by a broad range of customers in a wide range of settings.<\/p>\n<p>The company says Apollo will be able to deliver results as accurate as those generated in a specialized clinical lab in as little as one hour from sample preparation to read out. It is expected to detect and quantify multiple DNA- or RNA-based biomarkers in a variety of patient sample types. The technology has also been designed for integration with health care IT systems.<\/p>\n<p>The Apollo system, says Biocartis, has been developed in collaboration with Philips Corporate Technologies. Other collaborators include diagnostics company bioMerieux and Janssen Pharmaceuticals, a division of Johnson &amp; Johnson.<\/p>\n<p>Leading the investment round are Biocartis senior management including Rudi Pauwels, the company&#8217;s founder and CEO, as well as Peter Verhaeghe, managing partner of the Brussels law firm VVGB. Investors include Philips, Johnson &amp; Johnson Development Corporation, and the Wellcome Trust, among others.<\/p>\n<p>Read more: <a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=6735\" rel=\"prev\">Q3 Venture Investments Rise in China, Decline in Europe<\/a><\/p>\n<p>Photo: <a href=\"http:\/\/www.flickr.com\/photos\/m4dgroup\/6001102681\/in\/photostream\/\">MD4 Group\/Flickr<\/a><\/p>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biocartis, a diagnostic systems company in Lausanne, Switzerland says it completed raising \u20ac71 million (US$100 million) in series C equity funds, led by the company&#8217;s senior management and\u00a0 backed by current and new investors, as well as industrial collaborators. Series C financing is the third round of equity funding after start-up. Biocartis develops compact molecular [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[31,109,86,23,45,55,24,64,77,19],"class_list":["post-7002","post","type-post","status-publish","format-standard","hentry","category-finance","tag-biomedical","tag-computer-science","tag-engineering","tag-equity","tag-europe","tag-genomics","tag-investment","tag-life-sciences","tag-medical-device","tag-venture-capital"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/7002","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7002"}],"version-history":[{"count":6,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/7002\/revisions"}],"predecessor-version":[{"id":7008,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/7002\/revisions\/7008"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7002"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7002"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}